Biosensors, and in particular @entity413 and @entity880 sensors, are being widely developed and a few have been registered for continuous and semi-continuous use. Three @entity413 sensors, a transcutaneous sensor (GlucoWatch), a needle sensor (MiniMed) and microdialysis sensor (GlucoDay) have recently been evaluated among @entity6 @entity1 . The precise relationship between the biosensor signal and blood @entity413 is still a problem. For example, the utility of the subcutaneously placed needle sensor to detect nocturnal hypoglycaemia has been shown to be limited. The best subcutaneous site for placing the sensor needs to be systematically investigated. The three types of sensors have only been tested for a 3-5 day period. The utility of the microdialysis (separate from a direct link to biosensors) sensors among @entity6 @entity1 was established over a 3-week period following subcutaneous implantation. Furthermore, biosensors are being developed to monitor @entity880 in preterm babies, and @entity1 with ischaemia, @entity295 , or threatened organ damage (e.g. heart and @entity4798 ). In view of the current progress it is expected that within 5 years biosensor technology will have developed far enough to be used in the management of @entity6 and in intensive care units.

[Biosensors for continuous XXXX and @entity880 monitoring].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4798 :: ('MESH:D020520', 'Disease') :: ['brain infarction'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity413 :: (MESH:D005947,Chemical) :: ['glucose']
